Comparing SG&A Expenses: Summit Therapeutics Inc. vs Wave Life Sciences Ltd. Trends and Insights

Biotech SG&A Expenses: Summit vs. Wave Life Sciences

__timestampSummit Therapeutics Inc.Wave Life Sciences Ltd.
Wednesday, January 1, 201467952382999000
Thursday, January 1, 2015745424710393000
Friday, January 1, 20161034586215994000
Sunday, January 1, 20171698420326975000
Monday, January 1, 20181618729039509000
Tuesday, January 1, 20199299233.5448869000
Wednesday, January 1, 20201923200042510000
Friday, January 1, 20212361100046105000
Saturday, January 1, 20222670000050513000
Sunday, January 1, 20232821500051292000
Loading chart...

Data in motion

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Summit Therapeutics Inc. and Wave Life Sciences Ltd. from 2014 to 2023. Over this period, Wave Life Sciences consistently outpaced Summit Therapeutics in SG&A spending, with a peak in 2023 where their expenses were nearly 82% higher. Summit Therapeutics, however, showed a steady increase, with a notable 315% rise from 2014 to 2023. This trend highlights the strategic financial decisions each company has made in their quest for innovation and market leadership. Understanding these expenses provides insight into their operational strategies and potential future growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025